The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
The resurgence of platinum-based cancer chemotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198
Mechanisms of DNA damage, repair, and mutagenesis
Chatterjee, N., & Walker, G. C. (2017) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22087 · Cited by 2,039
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Synthesis, Functionalization, and Biomedical Applications of Multifunctional Magnetic Nanoparticles
Hao, R., Xing, R., Xu, Z., Hou, Y., Gao, S., & Sun, S. (2010) · Advanced Materials · doi:10.1002/adma.201000260 · Cited by 1,372
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy
Doane, T. L., & Burda, C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15260f · Cited by 1,098
He, C., Liu, D., & Lin, W. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00125 · Cited by 1,001
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00308-y · Cited by 972
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 906
He, C., Lu, K., Liu, D., & Lin, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4098862 · Cited by 885
Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin
Brown, S. D., Nativo, P., Smith, J.-A., Stirling, D., Edwards, P. R., Venugopal, B., Flint, D. J., Plumb, J. A., Graham, D., & Wheate, N. J. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908117a · Cited by 865
Bhirde, A. A., Patel, V., Gavard, J., Zhang, G., Sousa, A. A., Masedunskas, A., Leapman, R. D., Weigert, R., Gutkind, J. S., & Rusling, J. F. (2009) · ACS Nano · doi:10.1021/nn800551s · Cited by 853
Nanoscale Coordination Polymers for Platinum-Based Anticancer Drug Delivery
Rieter, W. J., Pott, K. M., Taylor, K. M. L., & Lin, W. (2008) · Journal of the American Chemical Society · doi:10.1021/ja803383k · Cited by 803
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
“mental effort culminated in 1978 with the approval of CDDP by the US Food and Drug Administration (FDA) for use in testicular and bladder cancer patients.(7) Since then, CDDP has been licensed worldwide for the treatment of multiple other solid neoplasms, including head and neck, lung, colorectal and ovarian cancers.”
BackgroundClinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs
Liu, W., & Gust, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35314h · Cited by 762
The Fanconi anaemia pathway: new players and new functions
Ceccaldi, R., Sarangi, P., & D'Andrea, A. D. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.48 · Cited by 720
Engineering nanomedicine for glutathione depletion-augmented cancer therapy
Xiong, Y., Xiao, C., Li, Z., & Yang, X. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00718h · Cited by 692
Targeting and delivery of platinum-based anticancer drugs
Wang, X., & Guo, Z. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35259a · Cited by 684
Ovarian damage from chemotherapy and current approaches to its protection
Spears, N., Lopes, F., Stefansdottir, A., Rossi, V, De Felici, M., Anderson, R. A., & Klinger, F. G. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmz027 · Cited by 657
Ma, P., Xiao, H., Yu, C., Liu, J., Cheng, Z., Song, H., Zhang, X., Li, C., Wang, J., Gu, Z., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b04269 · Cited by 649
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Shen, Z., Liu, T., Li, Y., Lau, J., Yang, Z., Fan, W., Zhou, Z., Shi, C., Ke, C., Bregadze, V. I., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b06201 · Cited by 633
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615
Recent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625
“Surgery remains the main treatment for cancer in which the bulk of the tumor is removed but the peripheral part cannot be completely eradicated due to the poor cellular differentiation in most of tumors[9-12].”
Backgroundvan Rijt, S. H., & Sadler, P. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.003 · Cited by 592
DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology
Cheung-Ong, K., Giaever, G., & Nislow, C. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.04.007 · Cited by 591
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance
Kurtova, A. V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S. P., Chen, F., Roh, T. T., Lay, E., Ho, P. L., et al. (2015) · Nature · doi:10.1038/nature14034 · Cited by 578
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
Dallas, N. A., Xia, L., Fan, F., Gray, M. J., Gaur, P., van Buren, G., Samuel, S., Kim, M. P., Lim, S. J., & Ellis, L. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2023 · Cited by 572
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
Verhaak, R. G. W., Tamayo, P., Yang, J.-Y., Hubbard, D., Zhang, H., Creighton, C. J., Fereday, S., Lawrence, M., Carter, S. L., Mermel, C. H., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65833 · Cited by 569
Cellular Responses to Cisplatin‐Induced DNA Damage
Basu, A., & Krishnamurthy, S. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/201367 · Cited by 569
Kolishetti, N., Dhar, S., Valencia, P. M., Lin, L. Q., Karnik, R., Lippard, S. J., Langer, R., & Farokhzad, O. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011368107 · Cited by 565
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
Inhibition of transcription by platinum antitumor compounds
Todd, R. C., & Lippard, S. J. (2009) · Metallomics · doi:10.1039/b907567d · Cited by 539
Dai, Y., Xiao, H., Liu, J., Yuan, Q., Ma, P., Yang, D., Li, C., Cheng, Z., Hou, Z., Yang, P., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja410028q · Cited by 529
Bruno, P. M., Liu, Y., Park, G. Y., Murai, J., Koch, C. E., Eisen, T. J., Pritchard, J. R., Pommier, Y., Lippard, S. J., & Hemann, M. T. (2017) · Nature Medicine · doi:10.1038/nm.4291 · Cited by 519
Metal-based anticancer chemotherapeutic agents
Muhammad, N., & Guo, Z. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.02.003 · Cited by 515
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies
Nobili, S., Mini, E., Landini, I., Gabbiani, C., Casini, A., & Messori, L. (2010) · Medicinal Research Reviews · doi:10.1002/med.20168 · Cited by 503
Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation
Garg, A. D., Nowis, D., Golab, J., Vandenabeele, P., Krysko, D. V., & Agostinis, P. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.003 · Cited by 496
Brunk, E., & Rothlisberger, U. (2015) · Chemical Reviews · doi:10.1021/cr500628b · Cited by 494
Advances in the field of π-conjugated 2,2′:6′,2″-terpyridines
Wild, A., Winter, A., Schlütter, F., & Schubert, U. S. (2011) · Chem. Soc. Rev. · doi:10.1039/c0cs00074d · Cited by 482
Biomedical and Biochemical Applications of Self-Assembled Metallacycles and Metallacages
Cook, T. R., Vajpayee, V., Lee, M. H., Stang, P. J., & Chi, K.-W. (2013) · Accounts of Chemical Research · doi:10.1021/ar400010v · Cited by 475
Yuan, Y., Kwok, R. T. K., Tang, B. Z., & Liu, B. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411811w · Cited by 474
Design and development of polymeric micelles with cleavable links for intracellular drug delivery
Wei, H., Zhuo, R.-X., & Zhang, X.-Z. (2013) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2012.07.002 · Cited by 474
TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma
Oshimori, N., Oristian, D., & Fuchs, E. (2015) · Cell · doi:10.1016/j.cell.2015.01.043 · Cited by 471
Poggio, F., Bruzzone, M., Ceppi, M., Pondé, N. F., La Valle, G., Del Mastro, L., de Azambuja, E., & Lambertini, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy127 · Cited by 468
Chemotherapy Side-Effects: Not All DNA Damage Is Equal
van den Boogaard, W. M. C., Komninos, D. S. J., & Vermeij, W. P. (2022) · Cancers · doi:10.3390/cancers14030627 · Cited by 458
Platinum nanoparticles in nanobiomedicine
Pedone, D., Moglianetti, M., De Luca, E., Bardi, G., & Pompa, P. P. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00152e · Cited by 454
Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
Hato, S. V., Khong, A., de Vries, I. J. M., & Lesterhuis, W. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3141 · Cited by 451
Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug
Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms9692 · Cited by 441
Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery
Zheng, Y.-R., Suntharalingam, K., Johnstone, T. C., Yoo, H., Lin, W., Brooks, J. G., & Lippard, S. J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5038269 · Cited by 440
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 440
Nam, J. S., Kang, M.-G., Kang, J., Park, S.-Y., Lee, S. J. C., Kim, H.-T., Seo, J. K., Kwon, O.-H., Lim, M. H., Rhee, H.-W., et al. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b05302 · Cited by 419
Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H., & Sparreboom, A. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.139 · Cited by 399
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation
Romero-Canelón, I., & Sadler, P. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400835n · Cited by 396
DNA repair mechanisms in cancer development and therapy
Torgovnick, A., & Schumacher, B. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00157 · Cited by 396
Dumbbell-like Au−Fe3O4 Nanoparticles for Target-Specific Platin Delivery
Xu, C., Wang, B., & Sun, S. (2009) · Journal of the American Chemical Society · doi:10.1021/ja900790v · Cited by 390
Liu, Y., Zheng, C., Huang, Y., He, M., Xu, W. W., & Li, B. (2021) · MedComm · doi:10.1002/mco2.55 · Cited by 387
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
Fennell, D. A., Summers, Y., Cadranel, J., Benepal, T., Christoph, D. C., Lal, R., Das, M., Maxwell, F., Visseren-Grul, C., & Ferry, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.003 · Cited by 382
Brock, P. R., Knight, K. R., Freyer, D. R., Campbell, K. C. M., Steyger, P. S., Blakley, B. W., Rassekh, S. R., Chang, K. W., Fligor, B. J., Rajput, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1110 · Cited by 380
Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes
Hall, M. D., Telma, K. A., Chang, K.-E., Lee, T. D., Madigan, J. P., Lloyd, J. R., Goldlust, I. S., Hoeschele, J. D., & Gottesman, M. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0247 · Cited by 377
Reversible Cell‐Specific Drug Delivery with Aptamer‐Functionalized Liposomes
Cao, Z., Tong, R., Mishra, A., Xu, W., Wong, G. C. L., Cheng, J., & Lu, Y. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200901452 · Cited by 372
Organometallic ruthenium-based antitumor compounds with novel modes of action
Ang, W. H., Casini, A., Sava, G., & Dyson, P. J. (2011) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2010.11.009 · Cited by 366
Plant flavonoids in cancer chemoprevention: role in genome stability
George, V. C., Dellaire, G., & Rupasinghe, H. P. V. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.11.007 · Cited by 362
Cisplatin resistance: Preclinical findings and clinical implications
Köberle, B., Tomicic, M. T., Usanova, S., & Kaina, B. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.07.004 · Cited by 361
Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy
Jaggi, A. S., & Singh, N. (2012) · Toxicology · doi:10.1016/j.tox.2011.10.019 · Cited by 358
Organometallic Half-Sandwich Iridium Anticancer Complexes
Liu, Z., Habtemariam, A., Pizarro, A. M., Fletcher, S. A., Kisova, A., Vrana, O., Salassa, L., Bruijnincx, P. C. A., Clarkson, G. J., Brabec, V., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2000932 · Cited by 357
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia
Zhang, W., Trachootham, D., Liu, J., Chen, G., Pelicano, H., Garcia-Prieto, C., Lu, W., Burger, J. A., Croce, C. M., Plunkett, W., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2432 · Cited by 357
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Yang, N., Kaur, S., Volinia, S., Greshock, J., Lassus, H., Hasegawa, K., Liang, S., Leminen, A., Deng, S., Smith, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1954 · Cited by 352
Platinum Drug Distribution in Cancer Cells and Tumors
Klein, A. V., & Hambley, T. W. (2009) · Chemical Reviews · doi:10.1021/cr9001066 · Cited by 351
The Potent Oxidant Anticancer Activity of Organoiridium Catalysts
Liu, Z., Romero‐Canelón, I., Qamar, B., Hearn, J. M., Habtemariam, A., Barry, N. P. E., Pizarro, A. M., Clarkson, G. J., & Sadler, P. J. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201311161 · Cited by 345
Cyclometalated iridium(III) luminescent complexes in therapy and phototherapy
Zamora, A., Vigueras, G., Rodríguez, V., Santana, M. D., & Ruiz, J. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.01.010 · Cited by 345
Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs
Howell, S. B., Safaei, R., Larson, C. A., & Sailor, M. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.063172 · Cited by 344
Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design
Reedijk, J. (2009) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200900054 · Cited by 343
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
Evers, B., Drost, R., Schut, E., de Bruin, M., van der Burg, E., Derksen, P. W. B., Holstege, H., Liu, X., van Drunen, E., Beverloo, H. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4953 · Cited by 335
Pogribny, I. P., Filkowski, J. N., Tryndyak, V. P., Golubov, A., Shpyleva, S. I., & Kovalchuk, O. (2010) · International Journal of Cancer · doi:10.1002/ijc.25191 · Cited by 334
Advances in cobalt complexes as anticancer agents
Munteanu, C. R., & Suntharalingam, K. (2015) · Dalton Transactions · doi:10.1039/c5dt02101d · Cited by 330
Circumventing Tumor Resistance to Chemotherapy by Nanotechnology
Liang, X.-J., Chen, C., Zhao, Y., & Wang, P. C. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_21 · Cited by 330
Tardito, S., Bassanetti, I., Bignardi, C., Elviri, L., Tegoni, M., Mucchino, C., Bussolati, O., Franchi-Gazzola, R., & Marchiò, L. (2011) · Journal of the American Chemical Society · doi:10.1021/ja109413c · Cited by 322
Hannon, M. J. (2007) · Pure and Applied Chemistry · doi:10.1351/pac200779122243 · Cited by 313
Min, Y., Li, J., Liu, F., Yeow, E. K. L., & Xing, B. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201308834 · Cited by 309
Cancer Stem Cells Contribute to Cisplatin Resistance in Brca1/p53 –Mediated Mouse Mammary Tumors
Shafee, N., Smith, C. R., Wei, S., Kim, Y., Mills, G. B., Hortobagyi, G. N., Stanbridge, E. J., & Lee, E. Y.-H. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5480 · Cited by 308
Roodhart, J. M. L., Daenen, L. G. M., Stigter, E. C. A., Prins, H.-J., Gerrits, J., Houthuijzen, J. M., Gerritsen, M. G., Schipper, H. S., Backer, M. J. G., van Amersfoort, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.010 · Cited by 305
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008866 · Cited by 305
Etemadmoghadam, D., deFazio, A., Beroukhim, R., Mermel, C., George, J., Getz, G., Tothill, R., Okamoto, A., Raeder, M. B., AOCS Study Group, et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1564 · Cited by 302
Adhireksan, Z., Davey, G. E., Campomanes, P., Groessl, M., Clavel, C. M., Yu, H., Nazarov, A. A., Yeo, C. H. F., Ang, W. H., Dröge, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms4462 · Cited by 297
Organic Cation Transporters in Health and Disease
Koepsell, H. (2020) · Pharmacological Reviews · doi:10.1124/pr.118.015578 · Cited by 297
Cell-to-cell variation in p53 dynamics leads to fractional killing.
Paek, A. L., Liu, J. C., Loewer, A., Forrester, W. C., & Lahav, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.025 · Cited by 292
Role of Autophagy in Cisplatin Resistance in Ovarian Cancer Cells
Wang, J., & Wu, G. S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.558288 · Cited by 291
Metadata
- Authors
- Kelland, L.
- Venue
- Nature Reviews Cancer
- Published
- 2007-07-12
- Volume
- 7
- Issue
- 8
- Pages
- 573-584
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2130177169
- Cited by
- 4,717
- References
- 85
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.